Holen Sie sich die Stockscreener-App
1.905
4.50%
-0.085
Schlusskurs vom Vortag:
$1.99
Offen:
$1.98
24-Stunden-Volumen:
324.11K
Relative Volume:
0.16
Marktkapitalisierung:
$95.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-144.01M
KGV:
-0.4751
EPS:
-4.01
Netto-Cashflow:
$-113.02M
1W Leistung:
+4.99%
1M Leistung:
+33.83%
6M Leistung:
-52.49%
1J Leistung:
-58.05%
1-Tages-Spanne:
$1.875
$1.99
1-Wochen-Bereich:
$1.63
$1.99
52-Wochen-Spanne:
$1.2905
$13.07
Biomea Fusion Inc Stock (BMEA) Company Profile
Firmenname
Biomea Fusion Inc
Sektor
Branche
Telefon
(650) 980-9099
Adresse
900 MIDDLEFIELD ROAD, REDWOOD CITY
Vergleichen Sie BMEA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.906 | 95.06M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.45 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.49 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.39 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.96 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-10-09 | Eingeleitet | Edward Jones | Buy |
| 2024-09-27 | Hochstufung | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Hochstufung | Truist | Hold → Buy |
| 2024-08-29 | Eingeleitet | CapitalOne | Overweight |
| 2024-06-11 | Herabstufung | Truist | Buy → Hold |
| 2024-06-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Eingeleitet | Truist | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-26 | Herabstufung | Jefferies | Buy → Hold |
| 2023-05-12 | Eingeleitet | Barclays | Overweight |
| 2023-03-29 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-28 | Bestätigt | H.C. Wainwright | Buy |
| 2023-02-24 | Eingeleitet | Citigroup | Buy |
| 2022-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Jefferies | Buy |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Biomea Fusion Inc Aktie (BMEA) Neueste Nachrichten
Market Today: Safran's Asset Sale and Biomea Fusion's Stock Offering - GuruFocus
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Top Midday Decliners - MarketScreener
Biomea Fusion stock falls after announcing public offering By Investing.com - Investing.com South Africa
Biomea Fusion stock falls after announcing public offering - Investing.com Australia
Biomea Fusion (BMEA) Reports Promising Preclinical Results for W - GuruFocus
Bitdeer, Biomea Fusion, Circle Internet - TradingView
Biomea Fusion (BMEA) Reports Promising Preclinical Results for Weight Loss Study | BMEA Stock News - GuruFocus
Biomea Fusion Reports Preclinical Data for BMF-650, a - GlobeNewswire
Biomea Fusion (BMEA) Receives Reaffirmed Buy Rating by D. Boral Capital | BMEA Stock News - GuruFocus
Biomea Fusion surges 76% following InvestingPro’s April Fair Value alert By Investing.com - Investing.com India
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates - Yahoo Finance
US Stocks Likely To Open Higher Despite Trump's 'Unconditional Surrender' Call: All Eyes On Powell As Experts Predict Inflation Will Limit Fed's Rate Cut Capacity - Benzinga
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Biomea Fusion tumbles on deep-discounted $40 mln equity raise - TradingView
Biomea Fusion Prices $40 Million Offering of Securities - marketscreener.com
Biomea Fusion (BMEA) Launches Public Offering with Warrants | BM - GuruFocus
Biomea Fusion (BMEA) Launches $40M Public Offering, Shares Drop - GuruFocus
Biomea Fusion sinks 25%, prices $40M stock offering (BMEA:NASDAQ) - Seeking Alpha
Diabetes Drug Developer Biomea Fusion Raises $40M in Strategic Public Offering with Warrant Sweetener - Stock Titan
(BMEA) Faces Pricing Challenge with New Offering | BMEA Stock News - GuruFocus
Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead - Asianet Newsable
Biomea Fusion Announces Pricing Of Public Offering Of Securities - marketscreener.com
Biomea Fusion Announces Pricing of Public Offering of Securities - GlobeNewswire Inc.
Biomea Fusion launches public offering of common stock and warrants By Investing.com - Investing.com India
Biomea Fusion Launches Public Offering of Securities; Shares Fall After Hours - marketscreener.com
Biomea Fusion tumbles on planned equity offering - TradingView
Biomea Fusion launches public offering of common stock and warrants - Investing.com
Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire
Biomea Fusion, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants - Nasdaq
Biomea Fusion Launches Major Public Offering with Jefferies to Advance Diabetes and Obesity Programs - Stock Titan
Biomea Fusion stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Purchased by Bank of America Corp DE - Defense World
D. Boral Capital Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
Biomea Fusion (BMEA) Receives Continued - GuruFocus
Biomea Fusion reports sustained responses in leukemia patients By Investing.com - Investing.com South Africa
Biomea Fusion (BMEA) Receives Continued "Buy" Rating from D. Bor - GuruFocus
Biomea Fusion (BMEA) Reveals Promising Clinical Data for Acute L - GuruFocus
Biomea Fusion reports sustained responses in leukemia patients - Investing.com Australia
Biomea Fusion (BMEA) Reveals Promising Clinical Data for Acute Leukemia Treatment | BMEA Stock News - GuruFocus
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 - The Manila Times
Biomea Fusion (BMEA) Sees Significant Indicative Borrow Rate Inc - GuruFocus
Largest borrow rate increases among liquid names - TipRanks
LUCA ANNOUNCES LEADERSHIP GROWTH AND BOARD TRANSITION - The Globe and Mail
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of “Buy” by Brokerages - Defense World
Wellington Management Group LLP Acquires Shares of 81,759 Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know - MSN
Biomea Fusion (NASDAQ:BMEA) Upgraded at Piper Sandler - Defense World
Biomea Fusion (NASDAQ:BMEA) Coverage Initiated by Analysts at Piper Sandler - Defense World
BMEABiomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - mx.advfn.com
BMEA: Piper Sandler Initiates Coverage with Overweight Rating an - GuruFocus
Finanzdaten der Biomea Fusion Inc-Aktie (BMEA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):